Integra LifeSciences (NASDAQ:IART) Downgraded by Wall Street Zen to Hold

Integra LifeSciences (NASDAQ:IART) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other brokerages also recently commented on IART. Weiss Ratings reiterated a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 29th. Wells Fargo & Company lowered their price target on shares of Integra LifeSciences from $13.00 to $12.00 and set an “equal weight” rating on the stock in a report on Friday, February 27th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus price target of $14.80.

Integra LifeSciences Stock Down 1.6%

Shares of NASDAQ IART opened at $9.73 on Friday. Integra LifeSciences has a 12-month low of $9.36 and a 12-month high of $24.36. The stock’s fifty day simple moving average is $11.72 and its two-hundred day simple moving average is $13.06. The stock has a market capitalization of $758.36 million, a PE ratio of -1.45 and a beta of 1.02. The company has a current ratio of 2.54, a quick ratio of 1.46 and a debt-to-equity ratio of 1.66.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Thursday, February 26th. The life sciences company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.79 by $0.04. The firm had revenue of $434.93 million during the quarter, compared to analyst estimates of $429.62 million. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The business’s revenue for the quarter was down 1.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.97 EPS. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. As a group, analysts expect that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Several hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Integra LifeSciences by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after purchasing an additional 1,975 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Integra LifeSciences in the 1st quarter worth approximately $277,000. Goldman Sachs Group Inc. raised its position in Integra LifeSciences by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock worth $36,515,000 after buying an additional 35,790 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Integra LifeSciences by 23.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock worth $5,373,000 after buying an additional 45,693 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in Integra LifeSciences during the 2nd quarter valued at approximately $632,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.